awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30376023-6C2421E1-BA81-4835-BD72-487CA6C68D40
Q30376023-6C2421E1-BA81-4835-BD72-487CA6C68D40
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30376023-6C2421E1-BA81-4835-BD72-487CA6C68D40
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me
P2860
Q30376023-6C2421E1-BA81-4835-BD72-487CA6C68D40
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30376023-6C2421E1-BA81-4835-BD72-487CA6C68D40
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f952e7d7dbee73fd96f7433fd922b2df4ac7233f
P2860
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.